Literature DB >> 28803177

Clusterin, a New Cerebrospinal Fluid Biomarker in Severe Subarachnoid Hemorrhage: A Pilot Study.

Norbert Wąsik1, Bartosz Sokół2, Marcin Hołysz3, Witold Mańko4, Robert Juszkat5, Piotr Paweł Jagodziński3, Roman Jankowski2.   

Abstract

BACKGROUND: Inflammation following subarachnoid hemorrhage (SAH) involves numerous mediators with biomarker properties. Preliminary studies indicated that clusterin, a multifunctional chaperon protein, was a potential biomarker in SAH. We aimed to clarify the status of clusterin in SAH.
METHODS: From 27 patients with severe SAH, 47 cerebrospinal fluid (CSF) samples were collected 0-3, 5-7, and 10-14 days after SAH. Control CSF was collected from 25 age- and sex-matched healthy control subjects undergoing spinal anesthesia for minor surgery. Clusterin concentrations were assayed using enzyme-linked immunosorbent assay and compared with inflammatory markers, imaging findings, and treatment outcome.
RESULTS: In healthy control subjects, mean CSF clusterin level (1908.5 ng/mL ± 36.0) was significantly higher than in the patient group (P < 0.001). In the patient group, mean clusterin level was 741.1 ng/mL ± 759.2 0-3 days, 601.6 ng/mL ± 507.2 5-7 days, and 639.2 ng/mL ± 446.8 10-14 days after SAH. Clusterin level failed to differentiate between good (Glasgow Outcome Scale 4-5) and poor (Glasgow Outcome Scale 1-3) outcomes 0-3 days and 10-14 days after SAH (P = 0.238 and P = 0.225), but significantly higher levels of CSF clusterin were found 5-7 days after SAH in patients with good outcome (P = 0.017). There was a significant correlation between CSF clusterin level 5-7 days after SAH and Glasgow Outcome Scale at 3 months (correlation coefficient = 0.633). The best correlation was found for World Federation of Neurological Societies scale (correlation coefficient = -0.741).
CONCLUSIONS: SAH is associated with immediate decrease in CSF clusterin concentrations. Clusterin level at one point was a good predictor of outcome, and it may serve as a biomarker.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Clusterin; Delayed cerebral ischemia; Inflammation; Subarachnoid hemorrhage

Mesh:

Substances:

Year:  2017        PMID: 28803177     DOI: 10.1016/j.wneu.2017.08.006

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Systemic inflammation in hemorrhagic strokes - A novel neurological sign and therapeutic target?

Authors:  Aisha R Saand; Fang Yu; Jun Chen; Sherry H-Y Chou
Journal:  J Cereb Blood Flow Metab       Date:  2019-04-08       Impact factor: 6.200

2.  Clusterin as a potential marker of brain ischemia-reperfusion injury in patients undergoing carotid endarterectomy.

Authors:  Joanna Iłżecka; Marek Iłżecki; Aneta Grabarska; Shawn Dave; Marcin Feldo; Tomasz Zubilewicz
Journal:  Ups J Med Sci       Date:  2019-08-28       Impact factor: 2.384

3.  CSF Proteomics of Patients with Hydrocephalus and Subarachnoid Haemorrhage.

Authors:  Bartosz Sokół; Bartosz Urbaniak; Bartosz Zaremba; Norbert Wąsik; Zenon J Kokot; Roman Jankowski
Journal:  Transl Neurosci       Date:  2019-10-02       Impact factor: 1.757

4.  TAT-HSP27 Peptide Improves Neurologic Deficits via Reducing Apoptosis After Experimental Subarachnoid Hemorrhage.

Authors:  Xiao-Yan Zhou; Jing-Yi Sun; Wei-Qi Wang; Shu-Xian Li; Han-Xia Li; Hui-Juan Yang; Ming-Feng Yang; Hui Yuan; Zong-Yong Zhang; Bao-Liang Sun; Jin-Xiang Han
Journal:  Front Cell Neurosci       Date:  2022-04-28       Impact factor: 5.505

5.  Association of cerebrospinal fluid protein biomarkers with outcomes in patients with traumatic and non-traumatic acute brain injury: systematic review of the literature.

Authors:  Carlos A Santacruz; Jean-Louis Vincent; Andres Bader; Luis A Rincón-Gutiérrez; Claudia Dominguez-Curell; David Communi; Fabio S Taccone
Journal:  Crit Care       Date:  2021-08-05       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.